Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales
Authors:
- Lucía Sánchez-PeñaLSLucía Sánchez-Peña
- Salud Rodríguez-PallaresSRSalud Rodríguez-Pallares
- Tania Blanco-MartínTBTania Blanco-Martín
- Gloria Pérez-RodríguezGPGloria Pérez-Rodríguez
- Pablo Aja-MacayaPAPablo Aja-Macaya
- Lucía González-PintoLGLucía González-Pinto
- Inmaculada López-HernándezILInmaculada López-Hernández
- Belén Aracil GarcíaBGBelén Aracil García
- Alejandro BeceiroABAlejandro Beceiro
- Germán BouGBGermán Bou
- Jorge Arca-SuárezJAJorge Arca-Suárez
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (7) , e0019526
Abstract
We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.Keywords
Funding Information
- Instituto de Salud Carlos III (CB21/13/00055)
- Instituto de Salud Carlos III (PI25/00116)
- Axencia Galega de Innovación (IN606A 2024/022)
- Axencia Galega de Innovación (IN606A 2025/020)
- Axencia Galega de Innovación (IN607A 2024/09)
- Axencia Galega de Innovación (IN607D 2021/12)
- Axencia Galega de Innovación (IN607D 2024/08)
- Instituto de Salud Carlos III (CM23/00095)
- Instituto de Salud Carlos III (CM23/00104)
- Instituto de Salud Carlos III (FI23/00074)
- Instituto de Salud Carlos III (JR21/00026)
- Instituto de Salud Carlos III (PI21/00704)
- Instituto de Salud Carlos III (PI22/01212)
- Instituto de Salud Carlos III (PI23/00851)
- Instituto de Salud Carlos III (PI24/00920)
This publication has 29 references indexed in Scilit:
- Transmission dynamics of Escherichia coli sequence type 131 in households—a one health prospective cohort studyNature Communications, 2025
- Cefiderocol “under siege”? Understanding the rise of NDM-mediated resistance to novel agentsChemical Science, 2025
- Multidrug-resistant Gram-negative bacterial infectionsThe Lancet, 2025
- Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditionsInternational Journal of Antimicrobial Agents, 2024
- Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trialThe Lancet Infectious Diseases, 2024
- Community-acquired bacteraemia by Klebsiella pneumoniae producing KPC-3 and resistant to ceftazidime/avibactamJournal of Global Antimicrobial Resistance, 2022
- Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencingInternational Journal of Antimicrobial Agents, 2022
- Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid β-Lactamase Inhibitor QPX7728Journal of Medicinal Chemistry, 2021
- Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D EnzymesJournal of Medicinal Chemistry, 2021
- Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellaeInternational Journal of Antimicrobial Agents, 2011